Atreca to Present at Upcoming Investor Conferences
Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), announced its participation in two upcoming investor conferences. The company will present at the Wedbush PacGrow 2022 Healthcare Conference on August 9, and at the Canaccord Genuity 42nd Annual Growth Conference on August 10. A live audio webcast of the Canaccord presentation will be available on Atreca's website, with an archived replay following the event. Atreca focuses on developing novel antibody-based immunotherapeutics, including its lead candidate ATRC-101, currently in a Phase 1b study for multiple solid tumor cancers.
- None.
- None.
SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate at the following upcoming investor conferences:
Wedbush PacGrow 2022 Healthcare Conference
August 9-10, 2022
Panel Discussion: For Your IOnly - Progress, Challenges in Immuno-Oncology: 11:20am EDT, August 9, 2022
Canaccord Genuity 42nd Annual Growth Conference
August 8-11, 2022
Presentation: 3:00pm EDT, August 10, 2022
A live audio webcast of the Canaccord presentation can be accessed through the Events & Presentations section of the Company's website at http://ir.atreca.com. An archived replay will be available on the Company's website for 30 days following the live broadcast.
About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding our strategy and future plans, including statements regarding the development of ATRC-101, ATRC-301, and our preclinical and clinical plans and the timing thereof. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.
Contacts
Atreca, Inc.
Herb Cross
Chief Financial Officer
info@atreca.com
Investors:
Alex Gray, 650-779-9251
agray@atreca.com
Media:
Julia Fuller, 858-692-2001
Julia@fordhutmanmedia.com
FAQ
What conferences will Atreca participate in during August 2022?
What is the date and time of Atreca's presentation at the Canaccord Genuity conference?
How can I access Atreca's live audio webcast?
What is the main focus of Atreca's development efforts?
What is ATRC-101 and its current status?
